Pharmaceuticals,Pharmaceuticals sector projects by Bafna Pharmaceuticals Ltd in
Project Information
4899
Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Ltd, A Chennai-Based Pharma Company, Today Informed The BSE That It Has Received Approval From Ghana Food And Drug Administration (FDA) To Market Omeran-20 Capsules (Gastro-Resistant Omerprazole Capsules 20mg). The Capsules Are Proton Pump Inhibitors Used In The Treatment Of Reflux Oesophagitis, Peptic Ulcer Disease, Gastroesophageal Reflux Disease, And Zollinger-Ellison Syndrome. The Drug Contains Generic Salt - Omeprazole And Its International Classification Of Diseases Is Omeprazole. The Company’s Chairman And Managing Director Mahaveer Bafna Said, "This Is A Major Milestone For Bafna Pharmaceuticals. It Will Strengthen Our Market In Ghana And Helps Us In Penetrating In Our Target Market Segment. We Have Already Received Product Approval From Ghana FDA In The Past And With The Entry Of Omeran.
Project Value
Refer document
Pre Project Activities Underway
Not Specified
India
Pharmaceuticals,Pharmaceuticals
Disclaimer :
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
